JP Morgan Chase’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-5,257
Closed -$622K 6857
2021
Q1
$622K Sell
5,257
-30
-0.6% -$3.55K ﹤0.01% 4543
2020
Q4
$624K Buy
5,287
+7
+0.1% +$813 ﹤0.01% 4252
2020
Q3
$587K Sell
5,280
-57,103
-92% -$6.13M ﹤0.01% 3909
2020
Q2
$6.37M Buy
62,383
+44,336
+246% +$4.74M ﹤0.01% 2268
2020
Q1
$1.95M Buy
18,047
+8,154
+82% +$937K ﹤0.01% 2986
2019
Q4
$1.15M Buy
9,893
+2,779
+39% +$322K ﹤0.01% 3751
2019
Q3
$814K Sell
7,114
-2,500
-26% -$249K ﹤0.01% 3946
2019
Q2
$917K Hold
9,614
﹤0.01% 3920
2019
Q1
$877K Sell
9,614
-2
-0% -$164 ﹤0.01% 3891
2018
Q4
$730K Buy
9,616
+2
+0% +$147 ﹤0.01% 3924
2018
Q3
$769K Sell
9,614
-4,400
-31% -$410K ﹤0.01% 4056
2018
Q2
$1.39M Buy
14,014
+8,800
+169% +$760K ﹤0.01% 3648
2018
Q1
$422K Sell
5,214
-2,113
-29% -$171K ﹤0.01% 4079
2017
Q4
$577K Sell
7,327
-1,373
-16% -$114K ﹤0.01% 4008
2017
Q3
$795K Buy
+8,700
New +$836K ﹤0.01% 3627
2016
Q4
Sell
-37,208
Closed -$4.63M 5272
2016
Q3
$4.63M Buy
+37,208
New +$4.39M ﹤0.01% 2305
2016
Q2
Sell
-20,644
Closed -$2.36M 5135
2016
Q1
$2.36M Buy
+20,644
New +$2.42M ﹤0.01% 2614
2015
Q3
Sell
-30,844
Closed -$3.55M 4222
2015
Q2
$3.55M Sell
30,844
-34,212
-53% -$3.59M ﹤0.01% 2593
2015
Q1
$6.21M Buy
+65,056
New +$4.87M ﹤0.01% 2200
2014
Q4
Sell
-5,234
Closed -$283K 4468
2014
Q3
$283K Buy
+5,234
New +$258K ﹤0.01% 3881

JP Morgan Chase's CBPO Position: Q2 2021 in Review

JP Morgan Chase sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 5,257 shares — an estimated $622K sold.

JP Morgan Chase first reported a position in CBPO in Q3 2014 and held it in 20 quarters. The position peaked at $6.37M in Q2 2020. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • JP Morgan Chase reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
  • JP Morgan Chase sold 5,257 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $622K.
  • JP Morgan Chase first reported a position in China Biologic Products Holdings, Inc. in Q3 2014 and held it in 20 quarters.
  • JP Morgan Chase's China Biologic Products Holdings, Inc. position peaked at $6.37M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.